Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06185985 · ClinicalTrials.gov registry record · Phase 4
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
A Phase 4 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 161
- Enrollment target
NCT06185985 is a Phase 4 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 161 participants.
The verdict
NCT06185985, a Phase 4 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 161 participants
- Enrollment target
Study Summary
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
Interventions
- DRUG SPN-812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06185985
The ClinicalTrials.gov registry entry for NCT06185985 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPN-812 is the first listed.
NCT06185985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06185985 about?
NCT06185985 is a clinical study titled "Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms". Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
What is the current status of trial NCT06185985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 161 participants. The study started on 2024-03-25. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT06185985?
The interventions under investigation include: SPN-812 (DRUG).
Who is sponsoring clinical trial NCT06185985?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.